Buprenorphine prolonged-release solution for injection (Buvidal®). HTA ID: 22056

Assessment Status Rapid Review complete
HTA ID 22056
Drug Buprenorphine
Brand Buvidal®
Indication Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
Assessment Process
Rapid review commissioned 09/08/2022
Rapid review completed 23/09/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Buvidal® not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.